HeartWare International (NSDQ:HTWR) is looking to get in on Dr. Stephen Oesterle, an Ex-Medtronic (NYSE:MDT) exec who moved to the venture capital firm New Enterprise Associates last Sept., saying this week that it expanded its board to accommodate Oesterle.
Oesterle will officially come aboard on Jan. 18, and his appointment included an expansion to HeartWare’s board from 8 to 9 members, according to the Framingham, Mass.-based company.
“Dr. Oesterle has extensive experience in the development of emerging medical therapies, with a broad strategic perspective in corporate management, as well as the clinical setting. Steve brings to HeartWare a tremendous clinical background in interventional cardiology, as well as a vision for the advancement of medical technology. His leadership, esteemed medical background and extensive relationships with researchers and innovators around the world will be of great value to HeartWare, as we seek to grow our business. Steve’s expertise will help support the advancement of HeartWare’s strategic objectives and our pipeline technologies, and we are looking forward to his contributions as our new Board member. We feel extraordinarily fortunate to have Steve joining our Board,” HeartWare CEO Doug Godshall said in an SEC filing.
Before moving to NEA, Oesterle served as senior veep of medicine and tech and a member of the executive committee at Medtronic, which he joined in 2002 and only left last year. Dr. Oesterle has served on more than 20 boards as a director or observer during his time at Medtronic. He also served as director of the invasive cardiology services as Massachusetts General Hospital and Stanford.
“The offer to join HeartWare’s board of directors was an opportunity that I eagerly accepted, as I am impressed by the strength of the company’s leadership and am enthusiastic about the potential to help HeartWare advance its prominence in the treatment of heart failure. I have followed HeartWare as it has grown to become a respected, global leader in the field of mechanical circulatory support, and I look forward to supporting the company through its next phase of growth to realize the company’s mission of developing revolutionary technologies for the treatment of heart failure for patients around the world,” Dr. Oesterle said in a prepared statement.
IsoRay CEO Babcock steps down
IsoRay (NYSE:ISR) said last week its CEO Dwight Babcock, who has served as CEO since 2009, has retired from his position. R&D veep Bill Cavanagh will serve as interim CEO as the company searches for a permanent replacement.
Haemonetics Q&A, regulatory exec veep bows out
Haemonetics (NYSE:HAE) said Monday its executive vice president of global quality and regulatory affairs has stepped down to pursue other opportunities. The company has not announced a replacement for the exiting exec.
GlucoTrack maker taps ex-Lumenis veep Cohen for COO
GlucoTrack maker Integrity Applications (OTC:IGAP) said yesterday it hired ex-Lumenis global sales veep Eran Cohen as its new chief operating officer. Cohen has 17 years of experience as a global exec, Integrity Applications said.
AdvaMed names Barney to lead new radiation therapy shop
AdvaMed said yesterday it named Shandi Barney as the lead to its newly created radiation therapy sector, which will focus on regulatory and payment challenges for that arm of the medical device industry.